AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01108575 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham IMST
Description: sham inspiratory muscle strength training
Study NCT01649856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
Study NCT01649856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CHOP
Description: CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
Study NCT01649856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab [MabThera/Rituxan]
Description: The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
Study NCT01649856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab [MabThera/Rituxan]
Description: 375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
Study NCT00179647 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: lenalidomide
Description: Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
Study NCT00179647 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dexamethasone
Description: Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
Study NCT04230382 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Diagnosis of diabetes (OGTT)
Description: Blood sample will be collected for glucose, HbA1c and magnesium. Standard OGTT will be conducted with 75g of glucose (repeated, if disgnostic).
Study NCT00622635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg
Description: Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study NCT00622635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to indacaterol
Description: Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
Study NCT00622635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol 50 μg
Description: Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
Study NCT00281840 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
Study NCT00281840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: docetaxel IV over 1 hour once a week for 8 weeks
Study NCT00281840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Description: 8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
Study NCT00281840 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: radiotherapy once daily, 5 days a week, for 8 weeks
Study NCT03609970 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: UVR (Solar simulated radiation)
Description: 1.25 SED Solar simulated radiation twice weekly
Study NCT03302130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mood induction (using own memories)
Description: Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
Study NCT03302130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arterial spin labeling MRI
Description: Single PLD PCASL
Study NCT03302130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physiological monitoring
Description: During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
Study NCT03933046 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSG
Description: polysomnography and urine analaysis for protein levels
Study NCT03166670 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: stool examination
Description: collection of stool specimen and microscopic examination for parasites
Study NCT03166670 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: real time polymerase chain reaction
Description: evaluation of genotype of cryptosporidium in stool specimen
Study NCT00912327 — intervention group
Intervention type: BIOLOGICAL
Intervention: Imprime PGG
Description: Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
Study NCT01494233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 250 mg LX1033 tablets
Description: 250 mg LX1033 tablets administered orally
Study NCT01494233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Matching placebo tablet administered orally
Study NCT04846907 — intervention group
Intervention type: OTHER
Intervention: Web-based survey
Description: Eligible participants received emails or text messages with links to a REDCap-created and managed web-based questionnaire
Study NCT00916617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bapineuzumab
Description: 5 mg/week subcutaneous bapineuzumab
Study NCT04435522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Maraviroc will be administered for seven days. Biomarkers of disease will be checked at time of enrollment, during and at the conclusion of therapy. The cytokine panel will consist of CCL5, IL-6, and Chitinase 3-like 1(Chi3l1).
Study NCT03093142 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham neurofeedback
Description: sham neurofeedback
Study NCT01461694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intense Pulsed Light (IPL)
Description: Half Face Treated with IPL
Study NCT01461694 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alexandrite Laser
Description: Half face treated with Alexandrite Laser
Study NCT02661581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: The intervention is lifestyle change. First, the peer leaders will be trained how to conduct diabetes self-management education and support sessions. During the first 3 months, all the participants will attend the diabetes self-management education sessions. The participants in the intervention arm will also receive diabetes self-management support sessions as well. In the end of the first 3 months, the intervention group participants will receive weekly support sessions for 9 months.
Study NCT01142739 — intervention group
Intervention type: OTHER
Intervention: Clinical variables
Description: Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
Study NCT01142739 — intervention group
Intervention type: OTHER
Intervention: Clinical variables
Description: Demography, Biological variables.
Study NCT01142739 — intervention group
Intervention type: OTHER
Intervention: Clinical variables
Description: Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
Study NCT05137639 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Description: PRF was only applied in the experimental arm to improve wound bed conditions
Study NCT01778309 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: n-acetylcysteine supplementation
Description: n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise~placebo administration: 500 mL orally, daily for eight days following exercise
Study NCT00757198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remifentanil
Description: remifentanil infusion
Study NCT00757198 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: remifentanil
Description: remifentanil infusion
Study NCT04355767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: SARS-CoV-2 convalescent plasma with neutralizing SARS-CoV2 antibodies titers of ≥1:160 administered via intravenous (IV) infusion.
Study NCT04355767 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline with multivitamin administered via intravenous (IV) infusion..
Study NCT03141346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sugar reduction health education program
Description: A health education program incorporating sugar reduction education and monitoring provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
Study NCT03141346 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control health education program
Description: Control health education program provided by a trained health educator over 24 months. The intervention program will be delivered by the health educator during in-person home visits, or virtually via phone or video calls.
Study NCT03141346 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home water delivery
Description: Home delivery of bottled water administered over 24 months
Study NCT03328286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly group meeting w/psychotherapist
Description: Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
Study NCT02662556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sufentanil sublingual tablet 30 mcg
Description: sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
Study NCT03620708 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Participants are provided with a 35 minute counseling session designed to increase motivation to quit smoking and then provided with a written referral for tobacco dependence treatment.
Study NCT02743598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Study NCT04120701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: Patients receive adjuvant chemotherapy every 2 weeks during 6 months: FOLFOX6m (5-FU, leucovorin and oxaliplatin).
Study NCT01141569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gamma-Secretase Inhibitor RO4929097
Description: Given PO
Study NCT03620708 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Replacement Therapy Sampling
Description: Participants are provided with a two-week sample of over-the-counter nicotine replacement therapy (i.e., nicotine lozenge and nicotine patch) and then provided with a written referral for tobacco dependence treatment.
Study NCT03620708 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Referral Only
Description: Participants are provided with a written referral for tobacco dependence treatment.
Study NCT03707223 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Interfaces Program
Description: career development program
Study NCT03707223 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: IPS
Description: supported employment using the individual placement and support (IPS) model
Study NCT00655993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: simvastatin
Description: 40 mg po daily
Study NCT00655993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 40 mg po daily
Study NCT01141569 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00405561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT2003
Study NCT01696123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLC601
Description: It was described
Study NCT02371538 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Donor Breastmilk
Description: Donor breastmilk will be obtained from the Mother's Milk Bank of New England.
Study NCT03075371 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 75 g of glucose dissolved in 300 ml of water
Study NCT03075371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300 ml of tap water
Study NCT02424799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 0.5% topical cream
Description: GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
Study NCT02424799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2646264 1% topical cream
Description: GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
Study NCT02424799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
Study NCT00998231 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
Study NCT00538473 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' influenza vaccine GSK576389A
Description: Single dose, intramuscular injection
Study NCT00538473 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluarix™
Description: Single dose, intramuscular injection
Study NCT01139242 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Body & Soul nutritional intervention
Description: Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
Study NCT01139242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental: newsletters and peer counseling
Description: Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
Study NCT01829490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ChAdOx1 85A
Description: Intramuscular injection
Study NCT01829490 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Intramuscular injection
Study NCT01145573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium or Placebo
Description: Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
Study NCT01145573 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Calcium or Placebo
Description: Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
Study NCT03166969 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holter 21 days
Study NCT02765958 — intervention group
Intervention type: DEVICE
Intervention: portable ECG devise
Study NCT03162120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine plus Metoprolol Combination
Description: Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
Study NCT03162120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FlecainidE pluS Metoprolol Combination
Description: FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
Study NCT01205373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 671800
Description: High dose oral drinking solution
Study NCT01873131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topical timolol maleate
Description: Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
Study NCT01873131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed dye laser
Description: A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
Study NCT02623530 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational intervention
Description: Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC.
Study NCT02623530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational intervention
Description: Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.~Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC.
Study NCT04027777 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aktiia.product-P0
Description: The optical signals at the wrist are recorded non-invasively by means of the Aktiia.product-P0 investigational device. The BP measurements are further determined from these optical signals and are compared to the reference double auscultation BP readings. A reference-control volume clamp BP reading is recorded simultaneously.
Study NCT04382599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text warning with square background
Description: The warning message is in white text on a black square background
Study NCT02625493 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Questionnaire containing a Best-worst Scaling scenario
Study NCT04382599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text warning with square background
Description: The warning message is in white text on a black square background
Study NCT02892981 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cardiopulmonary exercise test,hypoxia and hypercapnia test
Description: class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
Study NCT03921411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.
Study NCT03792685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normo-carbohydrate meal intake
Description: Subjects are going to receive the normo-carbohydrate meal.
Study NCT03792685 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-carbohydrate meal intake
Description: Subjects are going to receive the high-carbohydrate meal.
Study NCT00955929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo QHS and sildenafil and questionnaires
Description: Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.